Drug Profile
IMA 202
Alternative Names: IMA-202Latest Information Update: 09 May 2023
Price :
$50
*
At a glance
- Originator Immatics US
- Developer Immatics US; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cancer
- Phase I Solid tumours
Most Recent Events
- 17 Mar 2023 Immatics US and University of Texas M. D. Anderson Cancer Center complete a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Germany (IV) (NCT03441100)
- 02 Jun 2022 IMA 202 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US and Germany
- 02 Jun 2022 IMA 202 is available for licensing as of 02 Jun 2022. www.immatics.com 9359643